Economic cost

New American Diabetes Association Report Finds Annual Costs of Diabetes to be $412.9 Billion

Retrieved on: 
Wednesday, November 1, 2023
Epidemiology, American Association of Clinical Endocrinologists, American Diabetes Association, African Americans, Physician, Prevalence, Workforce, Presenteeism, Death, Absenteeism, ADA, Economic cost, Unemployment, Woman, Economy, Blood, Insulin, Pharmaceutical industry, Dietary supplement, Health care, Diabetes

ARLINGTON, Va., Nov. 1, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) published the Economic Costs of Diabetes in the U.S. in 2022 (Economic Report), a comprehensive analysis assessing the financial burden of living with diabetes in the United States. The Economic Report, which is published every five years, found that the total annual cost of diabetes in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs. People with diagnosed diabetes now account for one of every four health care dollars spent in the U.S.

Key Points: 
  • The Economic Report, which is published every five years, found that the total annual cost of diabetes in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs.
  • The Economic Report includes data on diabetes prevalence, total direct medical costs, and average annual medical expenditures.
  • National health care costs attributable to diabetes have increased by $80 billion in the past 10 years—from $227 billion in 2012 to $307 billion in 2022.
  • The full Economic Costs of Diabetes in the US in 2022 report is available online and will appear in the December issue of ADA journal, Diabetes Care®.

Fujitsu, Keio Research Institute at SFC lay foundation for a Trustable Internet

Retrieved on: 
Thursday, October 13, 2022
News, Method, Time, Economic cost, Tokenization (data security), Government, Architecture, Laboratory, Trust (social science), Health care, SFC, World Wide Web Consortium, Research, Information science, Convergence of random variables, Knowledge, Graduate school, Solution, Faculty, Industry, AI, US, Environment, Internet, Associate, Security, Keio University, Policy, Unintentional radiator, Online shopping, Pharmaceutical industry, Security printing, Mobile phone, Management, Cryptocurrency, Fujitsu, Nursing, W3C

Fujitsu and the Keio Research Institute at SFC initially presented the "Trustable Internet" concept at the W3C (World Wide Web Consortium) annual meeting and the W3C TPAC 2022 meeting (September 12-16, 2022) and defined the concept based on the opinions of various experts.

Key Points: 
  • Fujitsu and the Keio Research Institute at SFC initially presented the "Trustable Internet" concept at the W3C (World Wide Web Consortium) annual meeting and the W3C TPAC 2022 meeting (September 12-16, 2022) and defined the concept based on the opinions of various experts.
  • To address these issues, Fujitsu and the Keio Research Institute at SFC published their white paper outlining the concept of a "Trustable Internet" as a result of the research at their joint research base, the Trusted Internet Architecture Laboratory, which was established in April 2022.
  • - Director: Professor Osamu Nakamura (Faculty of Environment and Information Studies, Keio University)
    - Associate Director: Project Professor Shigeya Suzuki (Graduate School of Media and Governance, Keio University)
    - Researchers from the Keio Research Institute at SFC and Fujitsu (approx.
  • By 2021, the institute had more than 40 laboratories (transdisciplinary research groups with advanced research missions) and more than 30 SFC research consortiums (joint research deployed by the Keio Research Institute at SFC in conjunction with a number of external organizations), and together with approximately 500 senior and guest researchers from various industries, government, and academia, aims to develop unique research to create a vital society.

Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022

Retrieved on: 
Monday, June 6, 2022
Survival, Therapy, Technology, PSH, Immune system, Transplant, Haemophilia, Regenerative medicine, Potency (pharmacology), Partnership, American Diabetes Association, IPSC, Hypoglycemia, CM, Trial of the century, Portal vein, Immunosuppression, Association, Blood, HU, Type 1 diabetes, Conditional sentence, Degenerative disease, Cell, ADA, University, Patient, Injection, JAMA, TSX, Incidence, Prevalence, Ernest, C-peptide, University of Chicago, Thyroid disease, FSE, Thyroid, BMC Medicine, Diabetes Care, Disease, Nasdaq, GLOBE, Insulin, Clinical trial, Economic cost, Principal, Chicago (franchise), Protein, Pharmaceutical industry, Medical device, Dietary supplement, T1D, Diabetes

We are encouraged by the data demonstrating our Cell Pouch System has been well tolerated and multiple patients remain insulin independent.

Key Points: 
  • We are encouraged by the data demonstrating our Cell Pouch System has been well tolerated and multiple patients remain insulin independent.
  • We remain on track to further dose the three aforementioned subjects and to implement the higher capacity Cell Pouch System in the next implanted patients.
  • Sernovas Cell Pouch System is designed to address this vastly expanding need by providing a functional cure for the millions of people afflicted by insulin-dependent diabetes worldwide.
  • This partnership provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2).

Fraser Institute News Release: Raising an extra dollar of personal income tax revenue costs the Canadian economy $2.86

Retrieved on: 
Tuesday, April 26, 2022
Economic cost, Structure of the Canadian federal government, Forest Law Enforcement and Governance Program, Federation, Fraser Institute, Public policy, Government, GLOBE, Bangladesh Technical Education Board, Tax, Analysis, Entrepreneurship, Health insurance

The same is true for corporate taxes, with an additional ($1) dollar of corporate income tax raised by the federal government costing Canadians more than double that amount in lost economic activity ($2.02).

Key Points: 
  • The same is true for corporate taxes, with an additional ($1) dollar of corporate income tax raised by the federal government costing Canadians more than double that amount in lost economic activity ($2.02).
  • When governments raise tax rates, they affect the behaviour of workers, businesses, entrepreneurs, and investors.
  • So when a government raises tax rates, the actual cost to the economy is much higher, explained Bev Dahlby, senior fellow at the Fraser Institute and co-author of What Are the Economic Costs of Raising Revenue by the Canadian Federal Government?
  • In fact, for an additional dollar in personal income tax that the federal government collects, the actual cost to Canadiansbecause of those behavioural changesis $2.86, and $2.02 for an additional dollar in corporate income tax thats collected.

Innit Unveils Joint Solutions With Google Cloud for Health and Wellness

Retrieved on: 
Monday, March 28, 2022
Cloud, Chronic kidney disease, Pharmacy, Organization, Obesity, Nutrient, Korea Disease Control and Prevention Agency, CDC, Food technology, Chronic lung disease, Hypertension, Cancer, Economic cost, Alzheimer's disease, Health, CEO, Solution, Association, Google Cloud, Stroke, Allergen, GLOBE, Degenerative disease, Allergy, Center, Cooking, Meal, SAN, Conditional sentence, Partnership, Algorithm, Pharmaceutical industry, Food delivery, Dietary supplement, Diabetes, Innit

Diet-related disease has become a worldwide challenge, and few solutions have emerged to provide actionable assistance for everyday healthy eating.

Key Points: 
  • Diet-related disease has become a worldwide challenge, and few solutions have emerged to provide actionable assistance for everyday healthy eating.
  • *
    "As consumers seek out more ways to better manage their health and wellness, organizations have a unique opportunity to support consumer needs with personalized care experiences," said Paul Tepfenhart, Director, Global Grocery Solutions, Google Cloud.
  • Innit has developed personalized nutrition solutions, including tailored solutions for conditions such as type 2 diabetes, assisting millions of consumers worldwide.
  • Solutions are available immediately via the Google Cloud Marketplace.Please [email protected] for additional information.

AppliedVR Raises $36 Million Series B To Scale Comprehensive Virtual Reality Platform For Healthcare

Retrieved on: 
Thursday, November 11, 2021
People, Quality of life, COVID-19, University, Intelligence, Cleveland Clinic, National Academies Press, View, Cancer, Neuroscience, Science, Pharmacy, DOI, Health, Degenerative disease, CEO, Economic cost, Work, Technology, Internet research, Aircraft, Capital, University of California, San Francisco, Investment, Growth, Chronic pain, CA, Multimedia, Curriculum, Research, Sport, NIDA, Twitter, The Journal of Pain, LinkedIn, Therapy, Solution, Journal, Pain management, JMIR, Virtual reality, Diabetes, National academy, Education, Patient, VR, FDA, Medicaid, Poultry, Pharmaceutical industry, Medical device, Financial services

"For too long, we've relied on the notion that people need to take pills or rely on surgery to feel better and lead a better quality of life. At AppliedVR, we're building an unparalleled body of evidence for providers and payers to demonstrate that immersive therapeutics can fill the massive unmet need for patients who are frustrated by current treatment paradigms. And, we are starting with chronic pain, one of the most complex, costly conditions," said Matthew Stoudt, co-founder and CEO of AppliedVR. "Our goal is to make immersive therapeutics accessible to everyone, and this funding will help further expand our body of evidence, infrastructure and distribution platform, enabling patients and providers to take advantage of this next-generation therapeutic -- while also bringing down costs for payers."

Key Points: 
  • Virtual reality provides an immersive experience that has been proven to improve the lives of people experiencing pain.
  • And, we are starting with chronic pain, one of the most complex, costly conditions," said Matthew Stoudt, co-founder and CEO of AppliedVR.
  • "Virtual reality is now a smart, practical and effective therapy for healthcare because of innovations from companies like AppliedVR.
  • "As the market leader in developing virtual reality-based prescription digital therapies, we are delighted to be backing such an exceptional team at AppliedVR."

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

Retrieved on: 
Monday, September 27, 2021
Multifocal choroiditis and panuveitis, UC, Colectomy, Psoriasis, Hematochezia, Crohn's disease, Bechet, Ajinomoto, Adalimumab, Degenerative disease, Abdominal pain, Virology, Gastroenterology, LinkedIn, Adult, Disease, Immune system, Anemia, Twitter, Co-promotion, Ulcerative colitis, Maintenance, Fever, Inflammatory bowel disease, Erosion, Gastrointestinal disease, Patient, Uveitis, Pediatrics, Inflammation, YouTube, Marketing, Eisai, Neurology, Economic cost, Neuroscience, Rheumatoid arthritis, ACCA, Ankylosing spondylitis, Instagram, Diagnosis, Hidradenitis suppurativa, Juvenile idiopathic arthritis, Psoriatic arthritis, Bacteria, Prevalence, Pyoderma, AbbVie, Structural Damage, Pustular psoriasis, Pharmaceutical industry, Medicine, Health insurance, Vaccine, Aluminium, Fine chemical, Dietary supplement

TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").

Key Points: 
  • TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").
  • It remains a long-term condition that is not adequately controlled in some patients; more treatment options are needed.
  • The disease rarely develops in childhood, with an estimated prevalence in Japan of 15 per 100,000 between the ages of 0 to 19.
  • HUMIRA is a fully human anti-TNF-alpha monoclonal antibody.